Literature DB >> 26037015

Acyclovir-related kidney injury during alemtuzumab infusion.

Assunta Bianco1, Giovanni Gambaro, Paolo Maria Rossini, Massimiliano Mirabella.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26037015     DOI： 10.1007/s00415-015-7786-4

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

Review 1.  Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.

Authors:  Eva Havrdova; Dana Horakova; Ivana Kovarova
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

Review 2.  Antiviral drug-induced nephrotoxicity.

Authors:  Hassane Izzedine; Vincent Launay-Vacher; Gilbert Deray
Journal:  Am J Kidney Dis       Date:  2005-05       Impact factor: 8.860

Review 3.  CD52 antigen--a review.

Authors:  A Domagała; M Kurpisz
Journal:  Med Sci Monit       Date:  2001 Mar-Apr

4.  Risk of acute kidney injury from oral acyclovir: a population-based study.

Authors:  Ngan N Lam; Matthew A Weir; Zhan Yao; Peter G Blake; Michael M Beyea; Tara Gomes; Sonja Gandhi; Muhammad Mamdani; Ron Wald; Chirag R Parikh; Daniel G Hackam; Amit X Garg
Journal:  Am J Kidney Dis       Date:  2013-01-10       Impact factor: 8.860

5.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors:  Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

6.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

7.  Famciclovir substitution for patients with acyclovir-associated renal toxicity.

Authors:  Tin Han Htwe; Scott Bergman; Janak Koirala
Journal:  J Infect       Date:  2008-07-24       Impact factor: 6.072

Review 8.  Drug-induced crystal nephropathy: an update.

Authors:  Sri G Yarlagadda; Mark A Perazella
Journal:  Expert Opin Drug Saf       Date:  2008-03       Impact factor: 4.250

Review 9.  Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.

Authors:  Hans-Peter Hartung; Orhan Aktas; Alexey N Boyko
Journal:  Mult Scler       Date:  2014-10-24       Impact factor: 6.312
  9 in total
  1 in total

1.  No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.

Authors:  Luca Prosperini; Pietro Annovazzi; Laura Boffa; Maria Chiara Buscarinu; Antonio Gallo; Manuela Matta; Lucia Moiola; Luigina Musu; Paola Perini; Carlo Avolio; Valeria Barcella; Assunta Bianco; Deborah Farina; Elisabetta Ferraro; Simona Pontecorvo; Franco Granella; Luigi M E Grimaldi; Alice Laroni; Giacomo Lus; Francesco Patti; Eugenio Pucci; Matteo Pasca; Paola Sarchielli
Journal:  J Neurol       Date:  2018-09-26       Impact factor: 6.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.